1.
Langley R, Thaci D, Blauvelt A, Tsai T-F, Miller M, Yu J, Shen Y-K, You Y, Yang Y-W, Papp K, Puig L, Foley P. Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. J of Skin [Internet]. 2022Mar.4 [cited 2022Aug.11];6(2):s1. Available from: https://jofskin.org/index.php/skin/article/view/1516